Amgen

Featured Drug Company Program


Amgen Assist 360

888-427-7478
www.amgenassist360.com

Amgen FIRST STEP

888-657-8371
www.amgenfirststep.com

Amgen Assist 360 provides several support options for insured, uninsured, and underinsured patients who encounter financial hardships and cannot afford the Amgen medications they are prescribed.

Because individual copay foundations have their own eligibility criteria and application process, Amgen urges patients to contact each foundation directly for eligibility information.

Amgen Assist 360 offers patient support through independent foundations, sorted by drug (Table).

Table Amgen Oncology/Supportive Care Drugs
Drug Indications Patient support programs Contact information
Aranesp
(darbepoetin alfa)
Chemotherapy-induced anemia Amgen Assist 360 www.amgenassist360.com/hcp/aranesp-reimbursement-financial-assistance
Safety Net Foundation www.amgensafetynetfoundation.com
Blincyto
(blinatumomab)
Ph– relapsed or refractory B-cell precursor acute lymphoblastic leukemia Amgen Assist 360 www.amgenassist360.com/hcp/blincyto-financial-assistance
Safety Net Foundation www.amgensafetynetfoundation.com
Epogen
(epoetin alfa)
Chemotherapy-induced anemia Safety Net Foundation www.amgensafetynetfoundation.com
Imlygic
(talimogene laherparepvec)
Melanoma with unresectable cutaneous, subcutaneous, or nodal lesions Amgen Assist 360 www.amgenassist360.com/hcp/imlygic-reimbursement-financial-assistance
Amgen FIRST STEP https://amgenfirststep.com/imlygic-first-step
Safety Net Foundation www.amgensafetynetfoundation.com
Kyprolis
(carfilzomib)
Relapsed or refractory multiple myeloma, in combination with dexamethasone or with lenalidomide and dexamethasone Amgen Assist 360 www.amgenassist360.com/hcp/kyprolis-reimbursement-financial-assistance
Amgen FIRST STEP https://amgenfirststep.com/kyprolis-first-step
Safety Net Foundation www.amgensafetynetfoundation.com
Onyx 360 www.kyprolis-hcp.com/onyx360
Neulasta
(pegfilgrastim)
Growth factor support for patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs Amgen Assist 360 www.amgenassist360.com/hcp/neulasta-reimbursement-financial-assistance
Amgen FIRST STEP https://amgenfirststep.com/neulasta-first-step
Safety Net Foundation www.amgensafetynetfoundation.com
Neupogen
(filgrastim)
Growth factor support for patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs Amgen Assist 360 www.amgenassist360.com/hcp/neupogen-reimbursement-financial-assistance
Amgen FIRST STEP https://amgenfirststep.com/neupogen-first-step
Safety Net Foundation www.amgensafetynetfoundation.com
Nplate
(romiplostim)
Thrombocytopenia in patients with chronic immune thrombocytopenia Amgen Assist 360 www.amgenassist360.com/hcp/nplate-reimbursement-financial-assistance
Amgen FIRST STEP https://amgenfirststep.com/nplate-first-step
Safety Net Foundation www.amgensafetynetfoundation.com
Prolia
(denosumab)
Increase bone mass (1) in men with prostate cancer receiving androgen-deprivation therapy, or (2) in women with breast cancer receiving adjuvant aromatase inhibitor therapy Amgen Assist 360 www.amgenassist360.com/hcp/prolia-reimbursement-financial-assistance
Amgen FIRST STEP https://amgenfirststep.com/prolia-first-step
Safety Net Foundation www.amgensafetynetfoundation.com
Vectibix
(panitumumab)
Metastatic colorectal cancer with wild-type KRAS Amgen Assist 360 www.amgenassist360.com/hcp/vectibix-reimbursement-financial-assistance
Amgen FIRST STEP https://amgenfirststep.com/vectibix-first-step
Safety Net Foundation www.amgensafetynetfoundation.com
Xgeva
(denosumab)
Bone metastasis from solid tumors; unresectable giant-cell tumor of the bone; hypercalcemia of malignancy refractory to bisphosphonate therapy Amgen Assist 360 www.amgenassist360.com/hcp/xgeva-reimbursement-financial-assistance
Amgen FIRST STEP https://amgenfirststep.com/xgeva-first-step
Safety Net Foundation www.amgensafetynetfoundation.com
Ph– indicates Philadelphia chromosome–negative.

Amgen FIRST STEP

Amgen FIRST STEP helps qualified, commercially insured patients cover their deductible, coinsurance, or copay costs.

For the first dose of a covered medication, 100% of the patient’s combined copay, coinsurance, or deductible will be covered; for all subsequent doses, Amgen pays the patient’s combined out-of-pocket copay, coinsurance, or deductible in excess of $25 per dose.

Maximum program benefits are drug-specific and range from $3000 to $20,000 per patient per calendar year.

Safety Net Foundation

Amgen’s Safety Net Foundation is a nonprofit assistance program supported by Amgen that provides qualifying uninsured or underinsured patients with Amgen drugs at no cost.

For patients with government insurance, Medicare, or Medicaid, Amgen Assist 360 also helps by providing referrals to independent nonprofit foundations that can help with paying for medications.

The complete list of cancer drugs from Amgen is provided in the Table.

Eligibility

Amgen FIRST STEP

To qualify for the Amgen FIRST STEP program, a patient:
  • Must be prescribed an Amgen drug covered by the program
  • Must have private commercial health insurance coverage for the prescribed medication
  • Must not have government insurance (eg, Medicare, Medicaid)
  • Can have any income level
  • Must not be a resident of a state where coupons or copay programs are not valid.

Safety Net Foundation

To qualify for the Safety Net Foundation program, a patient must:

  • Be a resident of the United States or its territories
  • Satisfy income eligibility requirements
  • Have no or limited drug coverage
  • Not have any other insurance or financial support options.
In certain cases, patients who are underinsured or who have Medicare Part D coverage may qualify to receive support.

Application & Enrollment

Amgen FIRST STEP

Eligible patients must be enrolled in the individual drug-specific program for the Amgen medication they have been prescribed (which are collectively referred to as the Amgen FIRST STEP program).

Out-of-pocket costs for Amgen FIRST STEP must be associated with medications purchased and administered at a participating clinic or institution; the clinic or institution must be enrolled in the program before its patients can participate.

The healthcare provider submits the necessary materials and informs the patient if he or she qualified for the program. Amgen FIRST STEP program MasterCard can be used with mail-order and specialty pharmacies.

The program is valid for the enrolled patient’s entire course of treatment and does not require re-enrollment. However, for continued eligibility, the patient’s explanation of benefits must be submitted within 45 days of each swipe of the Amgen FIRST STEP copay coupon. If the explanation of benefits is delayed, contact the Help Desk (888-657-8371) for an extension.

Safety Net Foundation

To enroll in the Safety Net Foundation, patients must submit the Patient Application Form and any supporting materials. The patient and the provider are notified on the approval of the application and what costs will be covered.

Safety Net Foundation requires reapplication to the program each year. The foundation has 2 models of enrollment.

Prescription enrollment
This model applies to Amgen drugs that require a prescription and delivery of medication in advance of its administration. For the applicable Amgen drug, this model requires the submission of a drug’s prescription form completed by the prescriber or an original prescription to the foundation.

Replacement enrollment
This model applies to replacement drugs for physician-administered medications. In this model, the Amgen drug is first administered to qualifying foundation patients from the physician’s existing commercial stock, and then the replacement for this drug is ordered from the foundation. These drugs must be administered in an outpatient setting to be eligible for replacement.

Receiving Amgen Medications

Amgen oncology medications are distributed through different drug-­specific specialty pharmacies. For a list of authorized distributors visit www.amgen.com/products.

Safety Net Foundation

Amgen’s Safety Net Foundation has 2 ways of providing medications based on the enrollment model. Check online at http://www.amgensafetynetfoundation.com for drug-specific information.

Prescription enrollment
The foundation ships prescription drugs directly to the patient for all drugs included in this model, except for Prolia (denosumab), which is shipped directly to the provider.

Replacement enrollment
These drugs are sent directly to the prescriber.